Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P4TH
|
|||
| Former ID |
DCL000660
|
|||
| Drug Name |
Trastuzumab-DM1
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 3 | [1] | |
| Company |
Genentech
|
|||
| SuperDrug ATC ID |
L01XC03
|
|||
| SuperDrug CAS ID |
cas=180288691
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer. 2014 Mar 1;120(5):642-51. | |||
| REF 2 | Clinical pipeline report, company report or official report of Genentech (2009). | |||
| REF 3 | Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.